Full-Time
Fertility benefits management for employers
$65k - $75k/yr
No H1B Sponsorship
New York, NY, USA
Hybrid
Three days in the office per week required.
Bachelor's
See people who can refer or advise you
Progyny is a fertility benefits manager that partners with employers to offer comprehensive fertility and family-building services to employees. It provides a wide range of services including IUI, IVF, fertility preservation, adoption assistance, and surrogacy support, all integrated into employers’ existing benefits packages. The company makes money by signing contracts with employers, typically using a fixed-fee or per-employee-per-month pricing model, and it works to deliver better clinical outcomes to reduce overall treatment costs. Unlike broader health insurers, Progyny focuses specifically on fertility care and family-building, emphasizing measurable clinical results and seamless workflow within the benefits ecosystem. Its goal is to expand access to inclusive fertility benefits while improving outcomes and controlling costs for employers and employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
2008
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Performance Bonus
Family Planning Benefits
Fertility Treatment Support
Wellness Program
Mental Health Support
Company Social Events
Two healthcare companies with strong cash positions are attracting investor attention, whilst a fertility benefits provider faces challenges. Progyny holds $214.4 million in net cash, representing 14.2% of its market capitalisation. However, the company has struggled with underwhelming unit sales over the past two years and demonstrates below-average returns on capital. Trading at $27.95 per share, Progyny commands a 13.9x forward price-to-earnings ratio. Molina Healthcare maintains a net cash position of $1.22 billion, or 11.9% of market cap. The managed healthcare provider has achieved 13.7% annual revenue growth over five years, outpacing sector averages. Operating across 21 states, Molina serves low-income individuals through Medicaid, Medicare, and Marketplace programmes. Axos Financial, a digital banking and financial services company, holds $39.48 million in net cash, though this represents just 0.7% of its market capitalisation.
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. August 07, 2026 10:51:30 am NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Market Wire News envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected]
Progyny reported record quarterly revenue and adjusted EBITDA for Q2 2026. Second quarter revenue rose 5.3% year-over-year, or 11% excluding contributions from a large former client under a transition agreement in Q2 2025. The fertility benefits provider's gross margin expanded 180 basis points year-over-year, driven by efficiencies in care management and service delivery. Operating cash flow reached more than $50 million for the fourth time in five quarters. Progyny repurchased nearly 1.2 million shares for $31.5 million during the quarter under its $200 million programme. Since November, the company has bought back 10.8 million shares, reducing shares outstanding by approximately 12.5%. The company projects full-year 2026 revenue between $1.36 billion and $1.385 billion, representing growth of 5.5% to 7.5%.
Progyny, Inc. to present at the Canaccord Genuity Annual Growth Conference. NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny's investor relations website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: Investors: James Hart [email protected] Media: Alexis Ford [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Fertility benefits company Progyny reported second-quarter results for 2026, with revenue of $350.5 million, beating analyst expectations by 0.6% and representing 5.3% year-on-year growth. The company's non-GAAP earnings per share of $0.55 also exceeded estimates by 6.2%. Despite the positive quarterly results, Progyny's stock dropped 10.2% following disappointing forward guidance. The company's revenue forecast for the next quarter of $340 million came in 3% below analyst estimates. Progyny also lowered its full-year revenue guidance to $1.37 billion from $1.39 billion, a 0.9% decrease. Chief Executive Officer Pete Anevski attributed the strong quarterly results to member engagement trending toward the higher end of expectations.